Funding

Massachusetts-Based Remedium Bio Scores $10M in Initial Series A Funding

Aug 11, 2026 | By Devin Jacobs

SUMMARY

Remedium Bio raised $10 million in Series A funding.
The funding will support its lead programs and platform development.
Remedium Bio develops gene therapy treatments.

Remedium Bio, Inc., a Needham, MA-based provider of a gene therapy platform developing durable protein therapeutics, has raised $10 million in an initial Series A financing round led by Lifespan Vision Ventures.

The round also saw participation from Eli Lilly and Company and HKX Capital.

The company plans to use the fresh capital to advance its lead therapeutic programs, expand its platform technologies, and prepare for first-in-human clinical studies.

Funding Snapshot

Metric	Details
Fundraise Amount	$10 Million
Funding Round	Initial Series A
Lead Investor	Lifespan Vision Ventures
Other Investors	Eli Lilly and Company, HKX Capital
Company	Remedium Bio
Sector	Biotechnology / Gene Therapy
Headquarters	Needham, Massachusetts, US

RECOMMENDED FOR YOU

Funding

[Funding alert] PA-based NewSpring Secures over $180M for Fourth Growth Equity Healthcare Fund

Devin Jacobs

Jan 3, 2024

Funding

Clarium Secures $27M Series A Funding

Startuprise

May 10, 2025

Funding Wrap of the Week | American Startups Funding Roundup | January 20– January 24

Team SR

Jan 25, 2025

About Remedium Bio

Founded in 2020, Remedium Bio is building a platform designed to deliver durable protein therapeutics through minimally invasive subcutaneous administration.

The company's technology uses adipocytes, or fat cells, as a long-lasting site for therapeutic protein production. This approach is designed to provide controlled and sustained expression of therapeutic proteins, potentially reducing the need for frequent dosing in patients with chronic diseases.

Core offerings include:

Durable protein therapeutics
Gene therapy platform technology
Subcutaneous therapeutic delivery
Long-lasting therapeutic protein expression

Core Technologies / Products / Services

Capability / Product	Application / Use Case
Gene therapy platform	Long-term production of therapeutic proteins
Adipocyte-based expression	Using fat cells as a durable production site
Subcutaneous administration	Minimally invasive delivery
Adjustable dosing	Potential control over therapeutic protein levels

Leadership Comments

"Remedium has built a differentiated platform with the potential to address important limitations of chronic biologic therapy," said Andrew Worden, Founding Partner of Lifespan Vision Ventures. "We are proud to lead the Series A financing and support the company as it advances its pipeline toward clinical development and expands the potential of its platform."

"Lifespan Vision Ventures shares our belief that durable therapies have the potential to fundamentally improve the treatment of chronic disease," said Frank Luppino, Chief Executive Officer of Remedium Bio.